ArticleJournal of medical entomology2026
Semifield evaluation of autodissemination systems in Aedes notoscriptus and Culex quinquefasciatus and laboratory analysis of In2Care formulation effects.
Article in Journal of medical entomology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Urban mosquito control needs targeted tools that suppress population breeding in cryptic container habitats while reducing reliance on broad-spectrum insecticides. Autodissemination devices exploit oviposition behavior to transfer the insect growth regulator pyriproxyfen to larval sites and may be enhanced by adulticidal agents such as the entomopathogenic fungus Beauveria bassiana. We compared semifield efficacy of In2Care® Mosquito Stations and INZECTO Mosquito OviTraps + INZECTO pyriproxyfen chips against Aedes notoscriptus and Culex quinquefasciatus. We subsequently quantified the adult survival effects of pyriproxyfen, B. bassiana, and their combined formulation (In2Mix) in Ae. notoscriptus. Semifield trials used 4 × 4 m mesh tents in replicate blocks; 50 females per tent were exposed to In2Care stations, INZECTO OviTraps + INZECTO pyriproxyfen chips, or untreated controls with four surrounding oviposition cups. Cup water was bioassayed for emergence inhibition and analyzed with beta-binomial GLMMs. Adult females were force-exposed to treated nettings (pyriproxyfen-only, B. bassiana-only, In2Mix, control) and survival was analyzed with Cox regression. In semifield trials, In2Care reduced adult emergence relative to controls (logit estimate = 1.892, P < 0.0001) and was more effective than INZECTO (estimate = -0.990, P = 0.024); INZECTO also reduced adult emergence compared to controls (estimate = 0.902, P = 0.041). In laboratory assays, B. bassiana substantially increased mortality hazard (HR = 7.26). The In2Mix treatment produced a comparable effect (HR = 8.64), suggesting that most of the observed mortality in the combined treatment is driven by the B. bassiana component. Pyriproxyfen alone also significantly elevated mortality risk relative to the control, although the effect size was more moderate (HR = 2.35).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.